SynthesisBreast (Edinburgh, Scotland)2020
Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer.
Synthesis in Breast (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Percentage apparent diffusion coefficient change for early prediction of response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis, and a retrospective study.Quantitative imaging in medicine and surgery · 2025Article
- Breast Diffusion-weighted MR Imaging: Current Applications, Insights from Screening, and Future Directions.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Review
- Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response.Frontiers in oncology · 2025Article
- Adjuvant and Neoadjuvant Therapy for Breast Cancer: A Systematic Review.European journal of breast health · 2024Article
- Update on DWI for Breast Cancer Diagnosis and Treatment Monitoring.AJR. American journal of roentgenology · 2024Review
- Tumor infiltrating lymphocytes and radiological picture of the tumor.Medical oncology (Northwood, London, England) · 2023Review
- Predictive value of apparent diffusion coefficient for neoadjuvant chemotherapy in locally advanced colorectal cancer patients.Journal of gastrointestinal oncology · 2023Article
- Association between the apparent diffusion coefficient and the preoperative chemotherapy response of patients with locally advanced gastric cancer.Journal of gastrointestinal oncology · 2023Article
- Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Evaluation of Monoexponential, Stretched-Exponential and Intravoxel Incoherent Motion MRI Diffusion Models in Early Response Monitoring to Neoadjuvant Chemotherapy in Patients With Breast Cancer-A Preliminary Study.Journal of magnetic resonance imaging : JMRI · 2022Article
- Diffusion-Weighted Imaging of Different Breast Cancer Molecular Subtypes: A Systematic Review and Meta-Analysis.Breast care (Basel, Switzerland) · 2022Article
- Diffusion-weighted MRI to detect early response to chemoradiation in cervical cancer: A systematic review and meta-analysis.Gynecologic oncology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome reports indicated that apparent diffusion coefficient can predict pathologic response to treatment in breast cancer (BC). The purpose of the present meta-analysis was to provide evident data regarding use of ADC values for prediction of treatment response in BC.
methodsMEDLINE library, EMBASE and SCOPUS databases were screened for associations between ADC and treatment response for neoadjuvant chemotherapy in breast cancer (BC) up to March 2020. Overall, 22 studies met the inclusion criteria. For the present analysis, the following data were extracted from the collected studies: authors, year of publication, study design, number of patients/lesions, mean and standard deviation of the pretreatment ADC values. The methodological quality of the included studies was checked according to the QUADAS-2 instrument. The meta-analysis was undertaken by using RevMan 5.3 software. DerSimonian and Laird random-effects models with inverse-variance weights were used without any further correction to account for the heterogeneity between the studies. Mean ADC values including 95% confidence intervals were calculated separately for responders and non responders.
resultsThe acquired 22 studies comprised 1827 patients with different BC. Of the 1827 patients, 650 (35.6%) were reported as responders and 1177 (64.4%) as non-responders to the neoadjuvant chemotherapy. The pooled calculated pretreatment mean ADC value of BC in responders was 0.98 (95% CI = [0.94; 1.03]). In non-responders, it was 1.05 (95% CI = [1.00; 1.10]). The ADC values of the groups overlapped significantly.
conclusionPretreatment ADC alone cannot predict response to neoadjuvant chemotherapy in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.